Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

doi:10.1126/science.abb5920

GSTDTAP > 气候变化

DOI	10.1126/science.abb5920
	Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
	Erez N. Baruch; Ilan Youngster; Guy Ben-Betzalel; Rona Ortenberg; Adi Lahat; Lior Katz; Katerina Adler; Daniela Dick-Necula; Stephen Raskin; Naamah Bloch; Daniil Rotin; Liat Anafi; Camila Avivi; Jenny Melnichenko; Yael Steinberg-Silman; Ronac Mamtani; Hagit Harati; Nethanel Asher; Ronnie Shapira-Frommer; Tal Brosh-Nissimov; Yael Eshet; Shira Ben-Simon; Oren Ziv; Md Abdul Wadud Khan; Moran Amit; Nadim J. Ajami; Iris Barshack; Jacob Schachter; Jennifer A. Wargo; Omry Koren; Gal Markel; Ben Boursi
	2021-02-05
发表期刊	Science
出版年	2021
英文摘要	The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruch et al. and Davar et al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8+ T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients. Science , this issue p. [602][1], p. [595][2]; see also p. [573][3] The gut microbiome has been shown to influence the response of tumors to anti–PD-1 (programmed cell death–1) immunotherapy in preclinical mouse models and observational patient cohorts. However, modulation of gut microbiota in cancer patients has not been investigated in clinical trials. In this study, we performed a phase 1 clinical trial to assess the safety and feasibility of fecal microbiota transplantation (FMT) and reinduction of anti–PD-1 immunotherapy in 10 patients with anti–PD-1–refractory metastatic melanoma. We observed clinical responses in three patients, including two partial responses and one complete response. Notably, treatment with FMT was associated with favorable changes in immune cell infiltrates and gene expression profiles in both the gut lamina propria and the tumor microenvironment. These early findings have implications for modulating the gut microbiota in cancer treatment. [1]: /lookup/doi/10.1126/science.abb5920 [2]: /lookup/doi/10.1126/science.abf3363 [3]: /lookup/doi/10.1126/science.abg2904
领域	气候变化 ; 资源环境
URL	查看原文
引用统计	被引频次：762[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://119.78.100.173/C666/handle/2XK7JSWQ/314049
专题	气候变化资源环境科学
推荐引用方式 GB/T 7714	Erez N. Baruch,Ilan Youngster,Guy Ben-Betzalel,et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients[J]. Science,2021.
APA	Erez N. Baruch.,Ilan Youngster.,Guy Ben-Betzalel.,Rona Ortenberg.,Adi Lahat.,...&Ben Boursi.(2021).Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients.Science.
MLA	Erez N. Baruch,et al."Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients".Science (2021).